AstraZeneca PLC (AZN)vsMirum Pharmaceuticals Inc (MIRM)
AZN
AstraZeneca PLC
$161.42
+0.88%
HEALTHCARE · Cap: $263.09B
MIRM
Mirum Pharmaceuticals Inc
$100.65
+6.94%
HEALTHCARE · Cap: $6.46B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 10673% more annual revenue ($61.37B vs $569.61M). AZN leads profitability with a 17.0% profit margin vs -140.2%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
MIRM
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$161.42
$35.51 discount
Margin of Safety
+46.8%
Fair Value
$187.59
Current Price
$100.65
$86.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 43.3% year-over-year
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Elevated debt levels
Trading at 25.3x book value
ROE of -329.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : MIRM
The strongest argument for MIRM centers on Revenue Growth. Revenue growth of 43.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : MIRM
The primary concerns for MIRM are EPS Growth, Debt/Equity, Price/Book.
Key Dynamics to Monitor
AZN profiles as a mature stock while MIRM is a hypergrowth play — different risk/reward profiles.
MIRM carries more volatility with a beta of 0.48 — expect wider price swings.
MIRM is growing revenue faster at 43.3% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 30/100), backed by strong 17.0% margins. MIRM offers better value entry with a 46.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Mirum Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?